Aswathi Jyothkumar
Aswathi Jyothkumar has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Jainey Pj
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutical Chemistry, Deralakatte, Mangalore-575018, Karnataka, India
2 shared publications - Zakiya Fathima C.
Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Deralakatte, Mangaluru 575018, Karnataka, India
2 shared publications Abhijith T.
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutical Chemistry, Deralakatte, Mangalore-575018, Karnataka, India
1 shared publication- K. V. Gopika
Department of Pharmaceutical Chemistry, Al Shifa College of Pharmacy, Kizhattoor PO, Malappuram 679325, Kerala, India
1 shared publication S. Harshitha
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutical Chemistry, Deralakatte, Mangalore-575018, Karnataka, India
1 shared publication- Shankar G. Alegaon
Department of Pharmaceutical Chemistry, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India
1 shared publication
Latest Publications
- 26 September 2026
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- p. 1-26
Computational Design and Virtual Screening of Enumeration-Generated Benzothiazinone Derivatives as Cholinesterase Inhibitors Using Pharmacophore Modeling, Molecular Dynamics, DFT and ML-Based Predictive Modeling Analysis
Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are key cholinergic targets implicated in Alzheimer’s disease (AD), and simultaneous modulation of these enzymes represents a promising strategy for addressing cholinergic dysfunction. In this study, a comprehensive computational approach was employed to investigate benzothiazinone derivatives as potential cholinesterase inhibitors. Molecular docking of a virtual library against AChE (PDB ID: 6O4W) identified several compounds with favorable binding affinities, among which compounds 1d, 1k, and 1a were prioritized based on their overall docking performance and binding interactions. Compound 1d exhibited a favorable AChE docking score of −9.441 kcal/mol, comparable to the reference drug donepezil. To assess their binding affinity to BChE, the selected compounds were docked with BChE (PDB ID: 5DYW). This resulted in docking scores of −8.796 kcal/mol for 1a, −8.859 kcal/mol for 1k, and −8.748 kcal/mol for 1d. Further Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) binding free-energy calculations confirmed these compounds’ strong binding, emphasizing the role of hydrophobic and van der Waals interactions in stabilizing the complexes. The stability of the selected ligand–protein complexes was subsequently evaluated through 100 ns molecular dynamics simulations, with compounds 1k and 1d exhibiting stable interactions within the respective binding sites. Pharmacophore modeling identified the AHRRR_1 hypothesis, comprising one hydrogen-bond acceptor, one hydrogen-bond donor, and three aromatic ring features, with a selectivity score of 1.985 and a survival score of 5.975. Density functional theory (DFT) calculations revealed favorable electronic characteristics, including suitable HOMO–LUMO distributions and charge-transfer properties. ADMET analysis indicated favorable pharmacokinetic profiles for several derivatives, while CatPred-based machine-learning analysis predicted inhibition constants (Ki) in the micromolar range, suggesting moderate to strong binding potential. Overall, the integrated AChE/BChE docking, MM-GBSA, molecular dynamics, pharmacophore modeling, DFT, ADMET, and machine-learning analyses highlight benzothiazinone derivatives, particularly 1d, 1k, and 1a, as promising cholinesterase-targeting candidates and provide valuable structural insights for the rational development of potential therapeutic agents against AD.
- 26 September 2026
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- p. 1-26
Computational Design and Virtual Screening of Enumeration-Generated Benzothiazinone Derivatives as Cholinesterase Inhibitors Using Pharmacophore Modeling, Molecular Dynamics, DFT and ML-Based Predictive Modeling Analysis
Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are key cholinergic targets implicated in Alzheimer’s disease (AD), and simultaneous modulation of these enzymes represents a promising strategy for addressing cholinergic dysfunction. In this study, a comprehensive computational approach was employed to investigate benzothiazinone derivatives as potential cholinesterase inhibitors. Molecular docking of a virtual library against AChE (PDB ID: 6O4W) identified several compounds with favorable binding affinities, among which compounds 1d, 1k, and 1a were prioritized based on their overall docking performance and binding interactions. Compound 1d exhibited a favorable AChE docking score of −9.441 kcal/mol, comparable to the reference drug donepezil. To assess their binding affinity to BChE, the selected compounds were docked with BChE (PDB ID: 5DYW). This resulted in docking scores of −8.796 kcal/mol for 1a, −8.859 kcal/mol for 1k, and −8.748 kcal/mol for 1d. Further Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) binding free-energy calculations confirmed these compounds’ strong binding, emphasizing the role of hydrophobic and van der Waals interactions in stabilizing the complexes. The stability of the selected ligand–protein complexes was subsequently evaluated through 100 ns molecular dynamics simulations, with compounds 1k and 1d exhibiting stable interactions within the respective binding sites. Pharmacophore modeling identified the AHRRR_1 hypothesis, comprising one hydrogen-bond acceptor, one hydrogen-bond donor, and three aromatic ring features, with a selectivity score of 1.985 and a survival score of 5.975. Density functional theory (DFT) calculations revealed favorable electronic characteristics, including suitable HOMO–LUMO distributions and charge-transfer properties. ADMET analysis indicated favorable pharmacokinetic profiles for several derivatives, while CatPred-based machine-learning analysis predicted inhibition constants (Ki) in the micromolar range, suggesting moderate to strong binding potential. Overall, the integrated AChE/BChE docking, MM-GBSA, molecular dynamics, pharmacophore modeling, DFT, ADMET, and machine-learning analyses highlight benzothiazinone derivatives, particularly 1d, 1k, and 1a, as promising cholinesterase-targeting candidates and provide valuable structural insights for the rational development of potential therapeutic agents against AD.
- Open Access
- 7 September 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 562-569
Synthesis, In Silico and In Vitro Evaluation of Cholinesterase and Tyrosinase Inhibition of Benzothiazinones for Cognitive Disorders
Objective: Cognitive disorders, including Alzheimer’s disease (AD) are multifactorial conditions associated with cholinergic dysfunction and oxidative stress linked to abnormal melanogenesis. This study aimed to design, synthesise, and evaluate novel benzothiazinone derivatives for their dual inhibitory activity against acetylcholinesterase (AChE) and tyrosinase. Methods: Computational studies were performed using molecular docking on protein targets (PDB IDs: 6O4W, 5I38, and 1HD2), followed by MMGBSA for binding free-energy calculations, pharmacophore modelling and ADMET prediction. Designed compounds were synthesised via Schiff base intermediates and characterised using FTIR, ¹H NMR, ¹³C NMR, and mass spectrometry. In vitro AChE inhibition was evaluated using Ellman’s method, while tyrosinase inhibition was assessed by dopachrome formation at 492 nm. Antioxidant activity was determined using DPPH and hydrogen peroxide assays. All experiments were conducted in triplicate (n = 3), and results are expressed as mean±SD with 95% confidence intervals. Results: Docking studies revealed that compound 4a exhibited the highest binding affinities with scores of −6.72 kcal/mol (6O4W), −5.42 kcal/mol (5I38), and −4.48 kcal/mol (1HD2). In vitro, compound 4a demonstrated AChE inhibition (IC₅₀ = 6.05±1.03 µg/ml, n = 3; 95% CI: 3.49–8.61 µg/ml) and tyrosine inhibition (IC₅₀ = 23.00±0.98 µg/ml, n = 3; 95% CI: 20.56 – 25.44 µg/ml). Structure–activity relationship analysis indicated that substituents significantly influenced enzyme inhibition. Conclusion: Compound 4a emerged as a promising multifunctional lead compound with dual AChE and tyrosinase inhibitory activity, supported by both in silico and in vitro findings, highlighting its potential for further development in the management of cognitive disorders.
- 7 September 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 562-569
Open AccessSynthesis, In Silico and In Vitro Evaluation of Cholinesterase and Tyrosinase Inhibition of Benzothiazinones for Cognitive Disorders
Objective: Cognitive disorders, including Alzheimer’s disease (AD) are multifactorial conditions associated with cholinergic dysfunction and oxidative stress linked to abnormal melanogenesis. This study aimed to design, synthesise, and evaluate novel benzothiazinone derivatives for their dual inhibitory activity against acetylcholinesterase (AChE) and tyrosinase. Methods: Computational studies were performed using molecular docking on protein targets (PDB IDs: 6O4W, 5I38, and 1HD2), followed by MMGBSA for binding free-energy calculations, pharmacophore modelling and ADMET prediction. Designed compounds were synthesised via Schiff base intermediates and characterised using FTIR, ¹H NMR, ¹³C NMR, and mass spectrometry. In vitro AChE inhibition was evaluated using Ellman’s method, while tyrosinase inhibition was assessed by dopachrome formation at 492 nm. Antioxidant activity was determined using DPPH and hydrogen peroxide assays. All experiments were conducted in triplicate (n = 3), and results are expressed as mean±SD with 95% confidence intervals. Results: Docking studies revealed that compound 4a exhibited the highest binding affinities with scores of −6.72 kcal/mol (6O4W), −5.42 kcal/mol (5I38), and −4.48 kcal/mol (1HD2). In vitro, compound 4a demonstrated AChE inhibition (IC₅₀ = 6.05±1.03 µg/ml, n = 3; 95% CI: 3.49–8.61 µg/ml) and tyrosine inhibition (IC₅₀ = 23.00±0.98 µg/ml, n = 3; 95% CI: 20.56 – 25.44 µg/ml). Structure–activity relationship analysis indicated that substituents significantly influenced enzyme inhibition. Conclusion: Compound 4a emerged as a promising multifunctional lead compound with dual AChE and tyrosinase inhibitory activity, supported by both in silico and in vitro findings, highlighting its potential for further development in the management of cognitive disorders.